Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Modifying Parkinson's

Most drugs for Parkinson's disease target dopamine, which provides short-term, palliative treatment but is accompanied by neurological side effects and eventually loses efficacy as patients develop tolerance. Addex Pharmaceuticals S.A. believes its allosteric modulators of metabotropic glutamate receptor subtype 4, which act independently of dopaminergic neurons, may provide physicians with a disease-modifying therapeutic option.

Last week, Merck & Co. Inc. (MRK, Whitehouse Station, N.J.) in-licensed Addex's preclinical positive allosteric modulators of mGluR4 to treat PD and

Read the full 763 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE